Boston-based MAKScientific LLC has entered into an agreement with Biogen Idec to develop and commercialize drug candidates for the treatment of multiple sclerosis and other neurodegenerative diseases, Mass High Tech reports.
MAKScientific is a privately held companyfocused on the discovery of novel therapeutics modulating cannabinoid pathways. Under the agreement with Biogen, MAKScientific will be eligible to receive a fee of up to $3 million and up to an additional $31 million in milestone payments associated with the clinical development of the drug candidates, MHT reports.
